LEXARIA BIOSCIENCE CORP (LEXX) Fundamental Analysis & Valuation

NASDAQ:LEXX • US52886N4060

0.8288 USD
+0.05 (+7.09%)
At close: Mar 6, 2026
0.809 USD
-0.02 (-2.39%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LEXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LEXX. LEXX was compared to 193 industry peers in the Pharmaceuticals industry. While LEXX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. LEXX Profitability Analysis

1.1 Basic Checks

  • LEXX had negative earnings in the past year.
  • LEXX had a negative operating cash flow in the past year.
  • LEXX had negative earnings in each of the past 5 years.
  • LEXX had a negative operating cash flow in each of the past 5 years.
LEXX Yearly Net Income VS EBIT VS OCF VS FCFLEXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -178.37%, LEXX is not doing good in the industry: 87.05% of the companies in the same industry are doing better.
  • LEXX has a worse Return On Equity (-219.69%) than 74.09% of its industry peers.
Industry RankSector Rank
ROA -178.37%
ROE -219.69%
ROIC N/A
ROA(3y)-188.88%
ROA(5y)-137.97%
ROE(3y)-229.76%
ROE(5y)-162.22%
ROIC(3y)N/A
ROIC(5y)N/A
LEXX Yearly ROA, ROE, ROICLEXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • Looking at the Gross Margin, with a value of 100.00%, LEXX belongs to the top of the industry, outperforming 97.93% of the companies in the same industry.
  • LEXX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.9%
GM growth 5Y7.02%
LEXX Yearly Profit, Operating, Gross MarginsLEXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LEXX Health Analysis

2.1 Basic Checks

  • LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LEXX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, LEXX has more shares outstanding
  • There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LEXX Yearly Shares OutstandingLEXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
LEXX Yearly Total Debt VS Total AssetsLEXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • LEXX has an Altman-Z score of -9.90. This is a bad value and indicates that LEXX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -9.90, LEXX is not doing good in the industry: 68.39% of the companies in the same industry are doing better.
  • There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.9
ROIC/WACCN/A
WACC8.59%
LEXX Yearly LT Debt VS Equity VS FCFLEXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M

2.3 Liquidity

  • LEXX has a Current Ratio of 3.68. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.
  • LEXX's Current ratio of 3.68 is in line compared to the rest of the industry. LEXX outperforms 56.99% of its industry peers.
  • A Quick Ratio of 3.68 indicates that LEXX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.68, LEXX perfoms like the industry average, outperforming 58.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.68
LEXX Yearly Current Assets VS Current LiabilitesLEXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. LEXX Growth Analysis

3.1 Past

  • LEXX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.29%.
  • The Revenue has been growing slightly by 5.05% in the past year.
  • Measured over the past years, LEXX shows a quite strong growth in Revenue. The Revenue has been growing by 17.89% on average per year.
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)5.05%
Revenue growth 3Y39.51%
Revenue growth 5Y17.89%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.83% on average over the next years. This is a very strong growth
  • LEXX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 189.59% yearly.
EPS Next Y37.23%
EPS Next 2Y21.74%
EPS Next 3Y29.83%
EPS Next 5YN/A
Revenue Next Year-70.1%
Revenue Next 2Y44.81%
Revenue Next 3Y33.32%
Revenue Next 5Y189.6%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LEXX Yearly Revenue VS EstimatesLEXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
LEXX Yearly EPS VS EstimatesLEXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. LEXX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.
  • Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LEXX Price Earnings VS Forward Price EarningsLEXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEXX Per share dataLEXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • LEXX's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.74%
EPS Next 3Y29.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LEXX Dividend Analysis

5.1 Amount

  • LEXX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEXX Fundamentals: All Metrics, Ratios and Statistics

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (3/6/2026, 8:00:02 PM)

After market: 0.809 -0.02 (-2.39%)

0.8288

+0.05 (+7.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-13
Earnings (Next)04-13
Inst Owners6.9%
Inst Owner Change-0.94%
Ins Owners6.01%
Ins Owner Change0%
Market Cap20.63M
Revenue(TTM)522.00K
Net Income(TTM)-10.79M
Analysts82.86
Price Target4.59 (453.81%)
Short Float %2.79%
Short Ratio0.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.93%
Min EPS beat(2)18.65%
Max EPS beat(2)47.21%
EPS beat(4)3
Avg EPS beat(4)9.89%
Min EPS beat(4)-31.41%
Max EPS beat(4)47.21%
EPS beat(8)4
Avg EPS beat(8)0.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-37.74%
Min Revenue beat(2)-100%
Max Revenue beat(2)24.52%
Revenue beat(4)3
Avg Revenue beat(4)8.95%
Min Revenue beat(4)-100%
Max Revenue beat(4)86.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.62%
EPS NQ rev (1m)20.83%
EPS NQ rev (3m)36.67%
EPS NY rev (1m)0%
EPS NY rev (3m)23.08%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)-74.51%
Revenue NY rev (3m)-74.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.52
P/FCF N/A
P/OCF N/A
P/B 4.2
P/tB 4.48
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.02
BVpS0.2
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -178.37%
ROE -219.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-188.88%
ROA(5y)-137.97%
ROE(3y)-229.76%
ROE(5y)-162.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.9%
GM growth 5Y7.02%
F-Score4
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 294.13%
Cap/Sales 40.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.68
Altman-Z -9.9
F-Score4
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)212.54%
Cap/Depr(5y)178.07%
Cap/Sales(3y)49.65%
Cap/Sales(5y)45.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y37.23%
EPS Next 2Y21.74%
EPS Next 3Y29.83%
EPS Next 5YN/A
Revenue 1Y (TTM)5.05%
Revenue growth 3Y39.51%
Revenue growth 5Y17.89%
Sales Q2Q%-100%
Revenue Next Year-70.1%
Revenue Next 2Y44.81%
Revenue Next 3Y33.32%
Revenue Next 5Y189.6%
EBIT growth 1Y-47.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.33%
OCF growth 3YN/A
OCF growth 5YN/A

LEXARIA BIOSCIENCE CORP / LEXX FAQ

Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?

ChartMill assigns a fundamental rating of 3 / 10 to LEXX.


What is the valuation status for LEXX stock?

ChartMill assigns a valuation rating of 1 / 10 to LEXARIA BIOSCIENCE CORP (LEXX). This can be considered as Overvalued.


What is the profitability of LEXX stock?

LEXARIA BIOSCIENCE CORP (LEXX) has a profitability rating of 1 / 10.


What is the financial health of LEXARIA BIOSCIENCE CORP (LEXX) stock?

The financial health rating of LEXARIA BIOSCIENCE CORP (LEXX) is 6 / 10.